120 related articles for article (PubMed ID: 34841829)
1. Comparison of Different Molecular Subtypes with 14% Ki-67 Cut-off Threshold in Breast Cancer Patients of Pakistan- An Indication of Poor Prognosis.
Mushtaq M; Chaudry SS; Khalid Sheikh A; Khan N; Khattak A; Akbar A; Tanwani AK; Khaliq T; Malik MFA; Riaz SK
Arch Iran Med; 2021 Nov; 24(11):837-844. PubMed ID: 34841829
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
3. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
[TBL] [Abstract][Full Text] [Related]
5. Correlation of B-cell lymphoma 2 immunoexpression in invasive carcinoma of breast, no special type with hormone receptor status, proliferation index, and molecular subtypes.
Azmat H; Faridi J; Habib HM; Bugti UJ; Sheikh AK; Riaz SK
J Cancer Res Ther; 2022 Dec; 18(Supplement):S313-S319. PubMed ID: 36510982
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
7. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
9. MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers.
Sadeghian D; Saffar H; Mahdavi Sharif P; Soleimani V; Jahanbin B
Diagn Pathol; 2022 Feb; 17(1):24. PubMed ID: 35125121
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
11. Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance.
Sali AP; Sharma N; Verma A; Beke A; Shet T; Patil A; Pai T; Nair N; Parmar V; Gupta S; Hawaldar R; Desai SB
Clin Breast Cancer; 2020 Oct; 20(5):382-389. PubMed ID: 32467058
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
13. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
Maisonneuve P; Disalvatore D; Rotmensz N; Curigliano G; Colleoni M; Dellapasqua S; Pruneri G; Mastropasqua MG; Luini A; Bassi F; Pagani G; Viale G; Goldhirsch A
Breast Cancer Res; 2014 Jun; 16(3):R65. PubMed ID: 24951027
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
16. Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.
Caldarella A; Puliti D; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E
J Cancer Res Clin Oncol; 2013 Feb; 139(2):181-5. PubMed ID: 22961208
[TBL] [Abstract][Full Text] [Related]
17. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
18. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.
Inic Z; Zegarac M; Inic M; Markovic I; Kozomara Z; Djurisic I; Inic I; Pupic G; Jancic S
Clin Med Insights Oncol; 2014; 8():107-11. PubMed ID: 25249766
[TBL] [Abstract][Full Text] [Related]
19. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
